Inovio Pharmaceuticals Inc vs Revolution Medicines Inc. Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Revolution Medicines Inc. Common Stock trades at $189.76 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 359.4× Inovio Pharmaceuticals Inc's market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| INO | RVMD | |
|---|---|---|
Market Cap | $112.19M | $40.32B |
Volume | 3,201,278 | 4,855,734 |
Sector | Health | Health |
52-Week High | $2.65 | $221.15 |
52-Week Low | $0.66 | $47.50 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $83.51M | $37.02B |
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →